Abstract
AbstractWe report the case of a 72-year-old woman who presented with tuberculous arthritis during the setting of 177Lu-DOTATATE therapy for a grade-2 neuro-endocrine pancreatic tumor with liver metastases. We hypothesized that this recurrence might have been related to the occurrence of lymphopenia, which is common during PRRT. Indeed, though lymphopenia is frequently dismissed, it could lead to the development of opportunistic diseases and its severity should be examined, especially in case of abnormal clinical symptoms.
Publisher
Springer Science and Business Media LLC
Subject
Radiology, Nuclear Medicine and imaging,Molecular Medicine,Biophysics,Computer Science (miscellaneous)
Reference17 articles.
1. Anderson CW, Bennett JJ (2016) Clinical presentation and diagnosis of pancreatic neuroendocrine tumors. Surg Oncol Clin N Am 25:363–374
2. Bartacek A, Schutt D, Panosch B et al (2009) Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 13:760–766
3. Bodei L, Kidd M, Paganelli G et al (2015) Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 42:5–19
4. Campian JL, Ye X, Brock M et al (2013) Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest 31(3):183–188
5. De Cock KM, Grant A, Porter JD (1995) Preventive therapy for tuberculosis in HIV-infected persons: international recommendations, research, and practice. Lancet 345:833–836